Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose range from 5 mg/kg Q2W up to 18 mg/kg Q3WNo differences in efficacy were observed across different CLDN18.2 expression levels, with favorable overall safetyData anchor combination clinical strategy in first line (1L) gastric cancer, a $2B potential market1Confirming Q1 2026 plans to report topline Phase 1b dose ...

【深圳商报讯】（记者 陈燕青）最近几年，阿里巴巴、网易、京东等头部中概股纷纷赴港上市。如 今，中概股回流港股热度又有所升温。继禾赛科技之后，近日，天境生物、文远知行、小马智行等多只 在美股上市的中概股纷纷宣布赴港上市或公布进展。 10月17日，小马智行通过港交所上市聆讯，拟发行不超过1.021亿股。小马智行于2024年11月27日登陆 纳斯达克，目前市值超过70亿美元。 自2018年港交所上市制度改革以来，已有超30只中概股公司相继实现二次回港上市，包括阿里、京东、 网易、百度、携程等，几乎占了互联网行业的半壁江山。 根据记者梳理，中概股回流港股主要有3种方式：私有化退市后重新申请港股上市、在香港二次上市、 双重上市等。据统计，2018年以来共有34只中概股通过双重上市或二次上市登陆港股，其中22只为双重 上市，12只为二次上市。 对此，北方一家券商投行高管表示，"具体来看，私有化退市后重新申请上市需要的时间比较长，而且 需要有充足的资金完成私有化；二次上市主要通过存托凭证实现跨市场流通，通常以现有股份为基础， 无需重复发行新股，流程简单、所需时间短，合规要求可获多项豁免；而双重上市需承担两地上市的合 规成本 ...

Core Insights - I-Mab is transitioning to NovaBridge Biosciences, focusing on a global biotech innovation platform and plans to dual-list on the Hong Kong Stock Exchange and NASDAQ [1][2] - The company aims to bridge Chinese biotech innovations with global markets, enhancing the value of domestic innovations [2][7] - The "Hub-and-Spoke" model will be adopted, allowing for independent development of various product lines under a centralized management structure [3][4] Company Strategy - The new management team, led by CEO Dr. Fu Xiyong, is focused on recruiting talent to support the transformation and maximize the value of Chinese innovative drugs [2][5] - NovaBridge will leverage its parent company, Kangqiao Capital's resources, to support its global expansion and development strategy [4][6] - The company plans to target clinical-stage projects with high differentiation and competitive advantages, aiming for significant value increases during the clinical trial phases [9][10] Market Context - China has become a hotspot for biopharmaceutical innovation, with a significant increase in drug development activities since 2015, leading to a robust pipeline of innovative drugs [7][8] - The value of BD transactions in China's pharmaceutical sector has surged, with over $66.8 billion in overseas licensing agreements in the first half of 2025 [8] - The company aims to capture a larger share of the value chain, potentially increasing the returns from licensing agreements from 10% to as high as 50% [8][9] Competitive Landscape - NovaBridge's approach is compared to Roivant, but with a broader opportunity set in China, where numerous companies are engaged in drug development [10] - The efficiency and cost-effectiveness of conducting clinical trials in China provide a competitive advantage over Western markets [10] - The company plans to utilize both business development and self-commercialization strategies to maximize the value of its drug pipeline [10][11]

PresentationGood day, and welcome to the I-Mab Business Update Call. [Operator Instructions]. As a reminder, this conference call is being recorded and will be available for replay on the company's website. I would now like to turn the call over to PJ Kelleher from LifeSci Advisors. Please go ahead, Mr. Kelleher.PJ Kelleher Thank you, operator. Good afternoon, everyone, and thank you for joining the I-Mab business update call, which follows the press release issued today at 4:05 p.m. Eastern. Please note th ...

I-Mab Business Update Call Summary Company Overview - **Company**: I-Mab - **Industry**: Biotechnology - **Focus**: Transitioning from a clinical-stage China biotech to a global biotech platform with operations in both China and the U.S. [5][8] Key Points and Arguments Business Transformation Strategy - I-Mab is evolving into a global operating business, emphasizing a platform approach rather than a single molecule focus [6][8] - The company aims to leverage China's biotech innovation capabilities and U.S. clinical resources to enhance productivity and efficiency [8][9] Market Dynamics - China has become the leading country for clinical trials, surpassing the U.S. with a total transaction value of $94 billion in 2024, contributing over 60% of global licensing deal value in Q1 2025 [6][7] - The company is positioned to capitalize on this trend, recognizing the efficiency and quality of Chinese biotech by global pharmaceutical companies [7] Pipeline Overview - **Jewa Stomach**: A bispecific antibody targeting Claudin 18.2/4-1BB, showing a 71% overall response rate (ORR) compared to 47% for Nevo chemo and 40% for zolbetuximab [20][23] - Ongoing studies include a randomized phase two trial with 180 patients, expected to start in Q1 2026 [25] - **VIS 101**: Acquired for $37 million, targeting wet AMD and DME, with a potential market size of $20 billion to $30 billion [29][30] Financial Projections - Forecasted top sales for Jewa are approximately $2 billion, with additional opportunities in gastric, pancreatic, and biliary tract cancers potentially exceeding $3 billion [28] - The company aims to create value through licensing agreements post-proof of concept, with expected upfront payments around $50 million and potential total values reaching $1 billion for successful molecules [63] Strategic Partnerships - Collaboration with CBC Group, Asia's largest healthcare asset manager, enhances I-Mab's business development capabilities and governance practices [40][41] - The company has a systematic approach to screening assets, having identified over 550 opportunities and engaged with 116 [42] Future Directions - I-Mab plans to expand its therapeutic areas, with ophthalmology as the first focus, and aims to introduce 2 to 4 new molecules annually [53][54] - The hub-and-spoke model will allow for efficient resource allocation and faster turnaround times compared to traditional R&D models [58][59] Additional Important Content - The call emphasized the importance of a strong management team with diverse backgrounds in biotech and investment, which is crucial for executing the new strategy [18][36] - The company is committed to maintaining its existing clinical programs while expanding its portfolio, ensuring that current investors see continued value [46][47] This summary encapsulates the key insights from the I-Mab Business Update Call, highlighting the company's strategic transformation, market positioning, pipeline developments, and future growth plans.

New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwideIntention to pursue a Hong Kong initial public offering (IPO) to expand access to global capital and innovation through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX)Name change to be effective following shareholder approval, which is expected at the Extraordinary General Meeting (EG ...

Core Insights - Tianjing Biotech successfully completed nearly 600 million RMB in C+ round financing, aimed at advancing phase III clinical trials and market applications for first-tier products, while accelerating the development of second-tier global innovative drug candidates [1] - The financing reflects recognition of Tianjing Biotech's innovative capabilities and growth potential, as well as the strong appeal of the biomedical industry in Hangzhou Qiantang [1] Company Overview - Tianjing Biotech focuses on autoimmune diseases, tumors, and metabolic diseases, and has shown rapid growth since its strategic restructuring in early 2024 [1] - The company has established a diversified revenue model combining commercialization of near-market products, external licensing of innovative products, and CDMO services, effectively balancing high investment and risk in innovation [1] - Key milestones achieved include a strategic cooperation with Sanofi valued at approximately 1.7 billion RMB for the rights of Ureliximab in Greater China, and the breakthrough therapy designation for Punalizumab by the National Medical Products Administration [1] Product Pipeline - The innovative drug pipeline is entering a "harvest period" with a clear "dual-tier" layout, where the first tier includes six major products in late clinical stages, with new drug applications nearing completion [2] - The second tier consists of globally innovative projects and next-generation drugs expected to enter clinical trials between 2025 and 2026 [2] - The production base in Hangzhou plays a crucial role in supporting the entire industry chain, having fully operated its first phase and complied with GMP standards [2] Industry Context - The financing news for Tianjing Biotech is part of a broader trend, as multiple biopharmaceutical companies in Qiantang have also secured funding in the third quarter, indicating a vibrant development ecosystem in the region [3] - Companies like Zhejiang Ganaiwei Medical Technology and Hangzhou Derui Zhiyao Technology have also completed significant financing rounds, showcasing the robust vitality of the Qiantang biomedical industry [3]

Shares of immuno-oncology concern I-Mab (NASDAQ: IMAB ) have had a massive run in 2025 as enthusiasm has grown concerning its new lead asset, givastomig. The candidate in combo with chemo and Opdivo hit an ORR of 83% (10/12) acrossBret leads the investing group The Biotech Forum , in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfo ...

The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract related to updated data from the Phase 1 study of givastomig as a monotherapy in heavily pre-treated patients with gastroesop ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...